Seven Eight Capital LP Purchases Shares of 18,971 Lantheus Holdings, Inc. (NASDAQ:LNTH)

Seven Eight Capital LP purchased a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 18,971 shares of the medical equipment provider's stock, valued at approximately $1,523,000.

A number of other hedge funds have also recently added to or reduced their stakes in LNTH. Daiwa Securities Group Inc. bought a new stake in shares of Lantheus during the 1st quarter worth approximately $1,269,000. Clearbridge Investments LLC lifted its stake in Lantheus by 45.4% during the fourth quarter. Clearbridge Investments LLC now owns 538,782 shares of the medical equipment provider's stock worth $33,404,000 after purchasing an additional 168,114 shares during the last quarter. Nordea Investment Management AB boosted its holdings in shares of Lantheus by 42.6% in the 1st quarter. Nordea Investment Management AB now owns 47,322 shares of the medical equipment provider's stock valued at $2,932,000 after purchasing an additional 14,147 shares in the last quarter. Hancock Whitney Corp increased its stake in shares of Lantheus by 265.6% in the 1st quarter. Hancock Whitney Corp now owns 20,151 shares of the medical equipment provider's stock valued at $1,254,000 after purchasing an additional 14,639 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC acquired a new position in shares of Lantheus during the 2nd quarter worth $290,000. Institutional investors own 99.06% of the company's stock.

Insider Buying and Selling

In other Lantheus news, Director Gary J. Pruden sold 12,530 shares of Lantheus stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $95.04, for a total value of $1,190,851.20. Following the completion of the sale, the director now directly owns 11,978 shares in the company, valued at $1,138,389.12. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, President Paul Blanchfield sold 2,000 shares of the business's stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $96.39, for a total value of $192,780.00. Following the completion of the sale, the president now directly owns 98,980 shares of the company's stock, valued at approximately $9,540,682.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gary J. Pruden sold 12,530 shares of the business's stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $95.04, for a total value of $1,190,851.20. Following the sale, the director now owns 11,978 shares of the company's stock, valued at approximately $1,138,389.12. The disclosure for this sale can be found here. Insiders sold 40,852 shares of company stock valued at $3,922,001 over the last quarter. Insiders own 1.50% of the company's stock.

Analyst Ratings Changes

LNTH has been the topic of a number of recent analyst reports. Truist Financial decreased their target price on Lantheus from $141.00 to $135.00 and set a "buy" rating on the stock in a research report on Thursday, August 1st. Redburn Atlantic started coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They set a "buy" rating and a $175.00 price objective for the company. JMP Securities cut their target price on shares of Lantheus from $130.00 to $125.00 and set a "market outperform" rating on the stock in a research report on Thursday, August 1st. Leerink Partners upped their price target on shares of Lantheus from $106.00 to $127.00 and gave the stock an "outperform" rating in a report on Thursday, July 11th. Finally, B. Riley raised their price objective on Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a report on Thursday, July 25th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Lantheus currently has a consensus rating of "Moderate Buy" and an average price target of $126.00.

Lantheus Trading Up 1.4 %

NASDAQ:LNTH traded up $1.49 during trading hours on Friday, hitting $110.05. 1,162,275 shares of the company were exchanged, compared to its average volume of 1,020,474. The company has a fifty day simple moving average of $105.51 and a 200 day simple moving average of $84.10. Lantheus Holdings, Inc. has a one year low of $50.20 and a one year high of $126.89. The stock has a market capitalization of $7.63 billion, a price-to-earnings ratio of 16.80 and a beta of 0.50. The company has a current ratio of 4.68, a quick ratio of 4.41 and a debt-to-equity ratio of 0.55.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing analysts' consensus estimates of $1.68 by ($0.07). The firm had revenue of $394.10 million for the quarter, compared to analyst estimates of $382.12 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The business's revenue for the quarter was up 22.5% compared to the same quarter last year. During the same period in the prior year, the company posted $1.40 EPS. Sell-side analysts expect that Lantheus Holdings, Inc. will post 5.99 EPS for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.